{
    "clinical_study": {
        "@rank": "51971", 
        "arm_group": {
            "arm_group_label": "Supportive care (recombinant human hyaluronidase)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive recombinant human hyaluronidase SC on days 1, 3, 5, and 7 (Phase I) and then on days 1-21 (Phase II) in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This pilot phase I/II trial studies the side effects and the best dose of recombinant human\n      hyaluronidase and to see how well it works in treating lymphedema in patients with cancer.\n      Recombinant human hyaluronidase may reduce limb edema size in patients with lymphedema."
        }, 
        "brief_title": "Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer", 
        "condition": [
            "Lymphedema", 
            "Malignant Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Lymphedema"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Safety. II. Tolerability. III. To determine whether recombinant hyaluronidase\n      (recombinant human hyaluronidase) (rHUPH20) has a role in treatment of secondary lymphedema\n      resulting from treatment of malignancy.\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate for histologic and/or biomarker correlates of lymphedema or rHUPH20 response.\n\n      OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.\n\n      Patients receive recombinant human hyaluronidase subcutaneously (SC) on days 1, 3, 5, and 7\n      (Phase I) and then on days 1-21 (Phase II) in the absence of disease progression or\n      unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2\n\n          -  Unilateral upper limb secondary lymphedema\n\n          -  Women of child bearing potential must have a documented negative pregnancy test\n             within 2 weeks prior to day 1 of treatment and agree to use a non-hormonal form of\n             birth control during the duration of the trial therapy\n\n          -  Patients, or legal representative, must have the ability to understand and the\n             willingness to sign a written informed consent document\n\n          -  Patient or legal representative must agree to blood serum assessment including,\n             complete blood count (CBC) with differential; comprehensive metabolic panel and serum\n             osmolality at every sanctioned evaluation; additionally physician may require cardiac\n             evaluation with echocardiogram, electrocardiogram, brain natriuretic peptide or\n             urinalysis if deemed appropriate\n\n          -  Patient or legal representative must consent to multi-bio-frequency impedance\n             analysis (MFBIA); the details are to be covered in consent\n\n          -  Patient or legal guardian willing to sign consent for skin biopsies and phlebotomy\n\n        Exclusion Criteria:\n\n          -  Pregnant patients or actively breast-feeding\n\n          -  Patients with bilateral upper extremity edema\n\n          -  Patient with bilateral manipulation of axilla within the last 24 months\n\n          -  Patient with active infections\n\n          -  Patient undergoing concomitant treatment for upper extremity lymphedema, or who have\n             received treatment within the last 14 days\n\n          -  Patient with known allergic or hypersensitivity reaction to rHUPH20 or any\n             hyaluronidase extracts\n\n          -  Patient on concomitant diuretics or dihydropyridine class of calcium channel\n             blockers; if an alternative medication is available, patient can become eligible\n             after 3 half-lives of drug discontinued and patient remains medically stable\n\n          -  Patient has grade 2 or greater hypo-albuminemia, serum sodium greater than 150meq/L,\n             serum osmolality greater than 300mOsm/kg or blood urea nitrate/serum creatinine ratio\n             greater than 25, within 7 days of screening\n\n          -  Patient or family is unable or unwilling to self/home administer subcutaneous\n             experimental drug; study nurse or physician will train individuals on proper\n             administration techniques\n\n          -  Patient or caregivers who are unwilling or incapable of maintaining a detailed log of\n             number of injections, the date, time and site of administration\n\n          -  Patients with active malignancy; patient undergoing active treatment for malignancy\n             in the adjuvant setting are eligible; treatment can include chemotherapy, targeted\n             therapy or anti-hormonal therapy\n\n          -  Patient should be at least 4 weeks removed from surgery or radiation in affected arm\n\n          -  Patient with primary lymphedema; if edema can be explained by systemic or congenital\n             illnesses, that patient will not be eligible for this study\n\n          -  Patients must not have any concurrent condition which in the investigator's opinion\n             makes it inappropriate for the patient to participate in the trial or which would\n             jeopardize compliance with the protocol\n\n          -  Patients must not have received any investigational agents within 30 days prior to\n             commencing study treatment\n\n          -  Patients with active thrombophlebitis\n\n          -  Patients with pulmonary edema, congestive heart failure or pulmonary embolus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928030", 
            "org_study_id": "BRS0032", 
            "secondary_id": [
                "NCI-2013-01624", 
                "BRS0032", 
                "P30CA124435"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Supportive care (recombinant human hyaluronidase)", 
                "description": "Given SC", 
                "intervention_name": "recombinant human hyaluronidase", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Chemophase", 
                    "rHuPH20"
                ]
            }, 
            {
                "arm_group_label": "Supportive care (recombinant human hyaluronidase)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Supportive care (recombinant human hyaluronidase)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "contact": {
                "email": "gavidal@stanford.edu", 
                "last_name": "Gregory Vidal", 
                "phone": "504-909-1701"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "Mark D. Pegram", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Phase I/II Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy", 
        "overall_official": {
            "affiliation": "Stanford University Hospitals and Clinics", 
            "last_name": "Mark Pegram", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "The proportion of patient obtaining a clinically significant reduction in lymphedema (20% reduction in excess forearm volume) at a 95% confidence interval will be reported.", 
                "measure": "Overall response rate defined as the proportion of patients obtaining >= 20% reduction in excess forearm lymphedema", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928030"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Plasma concentration of recombinant human hyaluronidase", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at 30 minutes, and at 8 hours on days 1 and 7 (Phase I) and days 1, 8, 15 and 21 (phase II)"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}